CAS: 60514-48-9; (S)-3-Hydroxypropane-1,2-Diyl Dioctanoate

上下游产品

CAS号688021-88-7 (S)-SN-1,2-DI°C... | CAS号111-64-8 辛酰氯

📜(S)-Sn-1,2-二辛酰-3-苄基甘油置于palladium On Activated Charcoal 氢气体系中,用 甲醇 作为反应溶剂,化学反应生成 1,2-十八酰基-Sn-甘油
参考文献:作为溶血磷脂酸受体配体的第二代磷脂酸衍生物的合成和药理评价.
标题:作为溶血磷脂酸受体配体的第二代磷脂酸衍生物的合成和药理评价.
摘要:短链磷脂酸衍生物,焦磷酸二辛酯甘油酯(dgpp 8:0,1)和磷脂酸8:0(pa 8:0,2)先前被确定为亚型选择性lpa(1)和lpa(3)受体拮抗剂.最近,我们报道了在一系列脂肪醇磷酸酯(fap)中用硫代磷酸酯取代磷酸根基可以改善lpa Gpcr的激动剂和拮抗剂活性.在这里,我们报告pa 8:0类似物的立体异构体的合成及其在lpa Gpcr,Ppargamma和atx的生物学评估.结果表明,Lpa受体与甘油骨架修饰的配体立体选择性地相互作用.我们观测到由二辛基pa 8:0化合物产生的完全立体定向反应,其中(R)异构体是激动剂,(S)异构体是lpa Gpcr的拮抗剂.从这个系列中 我们将化合物13B确定为最有效的lpa(3)受体亚型选择性激动剂(ec(50)= 3 Nm),将8B确定为有效和选择性的lpa(3)受体拮抗剂(k(i)= 5 Nm)和atx抑制剂(ic(50)= 600 Nm
DOI:10.1016/j.Bmcl.2005.10.031

专利信息

专利号:US-8703812-B2
优先权日:2005-07-29
标 题 :Protein synthesis required for long-term memory is induced by PKC activation on days preceding associative learning
发明人：ALKON DANIEL L
权利人:ALKON DANIEL L; BRNI NEUROSCIENCES INST
摘要:The present invention provides methods of contacting a protein kinase C (PKC) activator with a PKC activator in a manner sufficient to stimulate the synthesis of proteins sufficient to consolidate long-term memory. The present invention also provides methods of contacting a protein kinase C (PKC) activator with a PKC activator in a manner sufficient to downregulate PKC.

专利号:US-2019209521-A1
优先权日:2006-07-28
标 题:Methods of stimulating cellular growth, synaptic remodeling and consolidation of long term memory
发明人：ALKON DANIEL
权利人:COGNITIVE RES ENTERPRISES INC
摘要:The present invention provides methods of slowing or reversing the loss of memory and learning comprising the steps of contacting an effective amount of a PKC activator with a protein kinase C (PKC) in a subject identified with memory loss slowing or reversing memory loss. The present invention provides methods of stimulating cellular growth, neuronal growth, dendritic growth, dendritic spine formation, dendritic spine density, and the translocation of ELAV to proximal dendrites, and synaptic remodeling. The present invention also provides methods of contacting a protein kinase C (PKC) activator with a PKC activator in a manner sufficient to stimulate the synthesis of proteins sufficient to consolidate long-term memory. The present invention also provides methods of contacting a protein kinase C (PKC) activator with a PKC activator in a manner sufficient to downregulate PKC.

专利号:US-2013331427-A1
优先权日:2006-07-28
标题:Methods of stimulating cellular growth, synaptic, remodeling and consolidation of long-term memory
发明人：ALKON DANIEL L
权利人:BRNI NEUROSCIENCES INST; BRNI NEUROSCIENCES INST
摘要:The present invention provides methods of slowing or reversing the loss of memory and learning comprising the steps of contacting an effective amount of a PKC activator with a protein kinase C (PKC) in a subject identified with memory loss slowing or reversing memory loss. The present invention provides methods of stimulating cellular growth, neuronal growth, dendritic growth, dendritic spine formation, dendritic spine density, and the translocation of ELAV to proximal dendrites, and synaptic remodeling. The present invention also provides methods of contacting a protein kinase C (PKC) activator with a PKC activator in a manner sufficient to stimulate the synthesis of proteins sufficient to consolidate long-term memory. The present invention also provides methods of contacting a protein kinase C (PKC) activator with a PKC activator in a manner sufficient to downregulate PKC.

专利号:US-5700450-A
优先权日:1988-03-30
标 题:Methods for enhancing melanin synthesis in melanocytes using diacyglycerols and uses thereof
发明人：GILCHREST BARBARA A; GORDON PHILIP R
权利人:UNIV BOSTON
摘要:Methods for enhancing melanin synthesis in melanocytes, thereby increasing the melanin content of melanocytes with subsequent transfer of the melanic pigments to keratinocytes resulting in increased pigmentation of vertebrate skin and hair; melanocytes with increased melanin content produced by these methods; and uses thereof are disclosed.

专利号:US-2005266068-A1
优先权日:2002-05-24
标题 :Cardiolipin molecules and methods of synthesis
发明人：AHMAD MOGHIS U; UKKALAM MURALI K; AHMAD IMRAN
权利人:NEOPHARM INC
摘要:The invention provides new synthetic routes for cardiolipin with different fatty acids and/or alkyl chains with varying chain length and also with or without unsaturation, particularly a short-chain cardiolipin. The methods comprise reacting a 1,2-O-sn-diacyl/1,2-O-sn-dialkyl glycerol or a 2-O-protected glycerol, with a phosphoramidite reagent or a phosphate triester to produce a protected cardiolipin, which is deprotected to prepare the short chain cardiolipin. The reaction schemes can be used to generate new variants of cardiolipin. The cardiolipin prepared by the present methods can be incorporated into liposomes, which can also include active agents such as hydrophobic or hydrophilic drugs. Such liposomes can be used to treat diseases or in diagnostic and/or analytical assays. Liposomes can also include ligands for targeting a particular cell type or specific tissue.

专利号:US-4975441-A
优先权日:1988-03-23
标 题:Lactams, their synthesis and use in cosmetic compositions
发明人：GIBSON WALTER T
权利人:UNILEVER PATENT HOLDINGS
摘要:A composition suitable for topical application to mammalian skin or hair for inducing, maintaining or increasing hair growth comprises: (i) a chemical inhibitor of glycosidase activity chosen from lactams having the structure: where A<1> and A<6> are -H, -CH3, - @@0, -CH2OT or @@@0 A<1> and A<6> being the same or different, and at least one of which being the group: @ @@o in a lactam ring; and where Q is -OT min , -NHT min or a lactam linkage to A<1> or A<6>; the Q groups being the same or different, and at least one of which is involved in a lactam linkage; and where T is the same or different and is chosen from -H, -CpH2p+1 or a metal ion, T min is -H or -COCpH2p+1, and p is an integer of from 1 to 22; provided that: where any of the Q groups is -OT min or -NHT min , then that group or groups can be of either stereochemical configuration with respect to the plane of the ring; and (ii) a cosmetically acceptable vehicle for the chemical inhibitor. Certain novel lactams are also claimed.